IP Library Granted Patent US 7,976,875
Granted Patent B2
US 7,976,875 · App. 12/490,246 · Granted Jul 12, 2011

Biofilm extracellular polysaccharide solvating system

Assignee: Medtronic Xomed, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,976,875
App. No.
12/490,246
Granted
Jul 12, 2011
Kind
B2
Abstract

The invention provides a solvating system for the removal of biofilms which solvates the extracellular polysaccharide matrix holding it to a surface. The aqueous solvating system comprises water, a metal ion sequestering agent, and a solvating agent for an extracellular polysaccharide matrix, which is gentle enough to be used directly on human tissues, but which may also be used on hard or soft non-tissue surfaces to breakdown, and/or remove biofilms.

Claims (25)

1. A method for the breakdown of a biofilm extracellular polysaccharide matrix, and for detachment or removal of the biofilm from a surface to which it is attached or adhered, which method comprises applying an aqueous solvating system solution to a biofilm on human or animal nasal passage or sinus tissue, or on a prosthetic system attached to such tissue, wherein said solution comprises water, an amount of metal ion sequestering agent and an amount of solvating agent for the extracellular polysaccharide matrix effective to break down such matrix and to detach or remove such biofilm from such surface, said solvating agent comprises a cationic or zwitterionic surfactant, and said solution has a pH greater than 5 and does not contain biocide harmful to such tissue.

2. A method according to claim 1 wherein said solution is applied to nasal passage tissue.

3. A method according to claim 1 wherein said solution is applied to sinus tissue.

4. A method according to claim 3 wherein said solution is applied to nasal passages or sinuses of persons with rhinosinusitius.

5. A method according to claim 1 wherein said solution is applied in the form of a spray, liquid, or gel.

6. A method according to claim 1 further comprising removing said solution by rinsing.

7. A method according to claim 1 further comprising removing said solution by allowing said solution to drain out of said tissue, by flushing or by aspiration.

8. A method according to claim 1 wherein said metal ion sequestering material removes an ion which bridges the biofilm extracellular polysaccharide matrix and binds polymer chains together.

9. A method according to claim 1 wherein said metal ion sequestering agent is a mild acid having a molarity of at least about 0.05 molar.

10. A method according to claim 1 wherein said metal ion sequestering agent has a molarity from about 0.05 to about 0.35 molar.

11. A method according to claim 1 wherein said metal ion sequestering agent comprises mandelic acid, 2-ketoglutaric acid, acetic acid, iminodiacetic acid, mucic acid, glycolic acid, fumaric acid, lactic acid, aspartic acid, phosphoric acid, pyruvic acid, chloroacetic acid, oxalic acid, oxamic acid, malic acid, dichloroacetic acid, phenylacetic acid, benzylic acid, maleic acid, succinic acid, chloromandelic acid, glutamic acid, nitrilotriacetic acid, boric acid, adipic acid, formic acid, glucuronic acid, salicylic acid, benzoic acid, benzoyl acid, phthalic acid, ketopimelic acid or hydrochloric acid.

12. A method according to claim 1 wherein said metal ion sequestering agent comprises citric acid.

13. A method according to claim 1 wherein said metal ion is selected from alkali metals, alkaline earth metals, and iron.

14. A method according to claim 1 further comprising a buffer.

15. A method according to claim 14 wherein said buffer comprises potassium chloride, glycine, potassium hydrogen phthalate, sodium acetate, potassium hydrogen phthalate, barbitone sodium or sodium citrate.

16. A method according to claim 14 wherein said metal ion sequestering agent comprises citric acid and said buffer comprises sodium citrate.

17. A method according to claim 14 wherein said buffer comprises up to about 25% of said solution.

18. A method according to claim 1 wherein said solvating agent is a cationic surfactant.

19. A method according to claim 1 wherein said solvating agent comprises hexadecyltrimethylammonium bromide.

20. A method according to claim 1 wherein said solvating agent is a zwitterionic surfactant.

21. A method according to claim 1 wherein said solvating agent comprises 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propane sulfonate, 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate, 3-(decyldimethlammonio) propanesulfonate inner salt or N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate.

22. A method according to claim 1 wherein said solvating agent is present in said solution in a strength of about 0.001 to about 0.69 molar.

23. A method according to claim 1 wherein said solvating agent is present in said solution in a strength of about 0.025 to about 0.13 molar.

24. A method according to claim 1 wherein said solvating agent is about 0.5 to about 20 weight percent of said solution.

25. A method according to claim 1 wherein said solvating system has a pH up to about 8.5.

Continuity (2)
Division 11431495 · May 10, 2006
Related Publication 20090258086A1 · Oct 15, 2009